Aduro Biotech Provides Update on CRS-207 Programs
December 12 2017 - 8:00AM
Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with
three distinct immunotherapy technologies, today provided an update
on its clinical development programs for CRS-207, a
first-generation proprietary attenuated strain of Listeria that has
been engineered to express the tumor-associated antigen mesothelin.
Based on preliminary results from its mesothelioma and ovarian
studies, as well as a business and commercial assessment, the
company has determined that it will not continue advancement of
CRS-207 and will wind down each of its trials in mesothelioma,
ovarian and gastric cancer. Aduro will be working closely with
investigators to proceed in a manner that is aligned with the best
interests of patients still being treated on these studies.
“We would like to thank the patients, their families, our
clinical investigators and staff for their time and commitment to
these trials, which will contribute important data to the field of
oncology. While we are disappointed with the results for CRS-207,
our clinical development program was designed to quickly generate
data that could inform timely decision-making and allow us to
prioritize our portfolio accordingly,” said Stephen Isaacs,
chairman and chief executive officer of Aduro Biotech. “We will
shift our focus and investment toward our STING agonist program,
B-select antibodies and personalized neoantigen approach with
pLADD. In our STING program in particular, there are several
additional clinical trials under consideration to complement our
ongoing Phase 1 dose escalation trial of ADU-S100 as well as our
combination study with Novartis’ PD-1 checkpoint inhibitor,
PDR-001. As a result of our portfolio decisions, we expect our
current cash balance to be sufficient to fund planned activities
for the next three years through 2020.”
Conference Call with Management TodayAduro’s
management will host a conference call to review its programs and
provide a general business update today at 8:30 am Eastern Time. To
participate in the conference call, please dial (844) 309-0604
(domestic) or (574) 990-9932 (international) and refer to
conference ID 2455008. Live audio of the conference call will be
simultaneously webcast and available to members of the news media,
investors and the general public under the investor section of the
Aduro website at investors.aduro.com.
The webcast will be archived and available for replay for one
month after the event.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's STING Pathway
Activator platform is designed to activate the STING receptor in
immune cells, resulting in a potent tumor-specific immune response.
ADU-S100 is the first STING Pathway Activator compound to enter the
clinic and is currently being evaluated in both a Phase 1
monotherapy study as well as a Phase 1b combination study with an
anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal
antibody platform is comprised of a number of immune modulating
assets in research and development, including BION-1301, an
anti-APRIL antibody. Aduro's pLADD program is based on proprietary
attenuated strains of Listeria that have been engineered to express
tumor neoantigens that are specific to an individual patient’s
tumor. Other Listeria strains for lung and prostate cancers are
being advanced by a partner. Aduro is collaborating with leading
global pharmaceutical companies to expand its products and
technology platforms. For more information, please visit
www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, our technology platforms, plans,
the potential for eventual regulatory approval of our product
candidates and our ability to fund planned activities through 2020.
In some cases, you can identify these statements by forward-looking
words such as “may,” “will,” “continue,” “anticipate,” “intend,”
“could,” “project,” “seek”, “expect” or the negative or plural of
these words or similar expressions. Forward-looking
statements are not guarantees of future performance and are subject
to risks and uncertainties that could cause actual results and
events to differ materially from those anticipated, including, but
not limited to, our history of net operating losses and uncertainty
regarding our ability to achieve profitability, our ability to
develop and commercialize our product candidates, our ability to
use and expand our technology platforms to build a pipeline of
product candidates, our ability to obtain and maintain regulatory
approval of our product candidates, our inability to operate in a
competitive industry and compete successfully against competitors
that have greater resources than we do, our reliance on third
parties, and our ability to obtain and adequately protect
intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our quarterly report on Form 10-Q for
the quarter ended September 30, 2017, which is on file with the
Securities and Exchange Commission. Any forward-looking statements
that we make in this press release speak only as of the date of
this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact: Sylvia WheelerSVP, Corporate Affairs510 809
9264
Media Contact: Aljanae Reynolds 510 809
2452 press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024